Kiora Pharmaceuticals Financial Results
Kiora Pharmaceuticals reported third quarter 2026 financial results and highlighted the strategic in-licensing of KIO-401, a late-stage oral neuroprotective asset for retinal diseases. The company ended the quarter with $16.3 million in cash and is preparing for a Phase 3 registration trial for KIO-401 in patients with Central Retinal Artery Occlusion (CRAO).
“The addition of KIO-401 transforms Kiora into a late-stage retinal therapeutics company. We are building on the significant amount of CMC, non-clinical and clinical data that already exists on KIO-401 through Senju’s previous and ongoing efforts. With exclusive rights outside Asia, we are preparing for a single, phase 3, registration trial of KIO-401 in patients across the United States, Europe and other territories.”
Brian M. Strem, Ph.D., President and Chief Executive Officer